Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 15:15:1359088.
doi: 10.3389/fpsyt.2024.1359088. eCollection 2024.

Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials

Shuping Fang #  1 , Xin Yang #  1 , Wei Zhang  1   2   3
Affiliations

Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials

Shuping Fang et al. Front Psychiatry. .

Abstract

Introduction: Psilocybin is a classic psychedelics, which has been shown to have antidepressant effects by many studies in recent years. In this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression.

Methods: We searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov for clinical trials of psilocybin for depression (updated to 4 October, 2023). Effect size Hedges' g was used as an indicator of efficacy, and other outcomes included response rate, drop-out rate, and adverse events.

Results: A total of 10 studies were finally included in systematic review. 8 studies were included in the meta-analysis, involving a total of 524 adult patients, and produced a large effect size in favor of psilocybin (Hedge's g =-0.89, 95% CI -1.25~-0.53, I² = 70.19%, P<0.01). The therapeutic effects of psilocybin increase with increasing doses. Adverse events caused by psilocybin are generally transient and reversible, but serious adverse events also may occur.

Discussion: Our study shows that psilocybin has both short-term and long-term antidepressant effects and holds promise as a potential complementary or alternative therapy for depression, probably. Further research may reveal more about its therapeutic potential.

Keywords: acceptability; depression; efficacy; psilocybin; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Prisma flow-chart of study selection process.
Figure 2
Figure 2
Risk of bias assessment of the included studies. Green indicates low risk of bias, yellow indicates unclear risk of bias, and red indicates high risk of bias.
Figure 3
Figure 3
Meta-analysis of psilocybin compared to placebo/low-dose psilocybin for treating primary or secondary depression.
Figure 4
Figure 4
Overall subgroup analysis results based on participant type, dose and duration.
Figure 5
Figure 5
Meta-analysis of psilocybin compared to placebo/low-dose psilocybin for treating primary or secondary depression: subgroup analysis based on participant type.
Figure 6
Figure 6
Meta-analysis of psilocybin compared to placebo/low-dose psilocybin for treating primary or secondary depression: subgroup analysis based on duration time.
Figure 7
Figure 7
Meta-analysis of psilocybin compared to placebo/low-dose psilocybin for treating primary or secondary depression: subgroup analysis based on dosage.
See this image and copyright information in PMC

References

    1. World Health Organization . Depression. Available online at: https://www.who.int/health-topics/depression#tab=tab_1 (Accessed April 15, 2023).
    1. World Health Organization . International Classification of Diseases 11th Revision . Available online at: https://icd.who.int/en (Accessed April 18, 2023).
    1. Malhi GS, Mann JJ. Depression. Lancet (London England). (2018) 392:2299–312. doi: 10.1016/S0140-6736(18)31948-2. - DOI - PubMed
    1. World Health Organization . WHO Director-General’s opening remarks at the Mental Health at Work panel, World Economic Forum – 18 January 2023 . Available online at: https://www.who.int/director-general/speeches/detail/who-director-genera... (Accessed April 20, 2023).
    1. Li M, Yao X, Sun L, Zhao L, Xu W, Zhao H, et al. Effects of electroconvulsive therapy on depression and its potential mechanism. Front Psychol (2020) 11:80. doi: 10.3389/fpsyg.2020.00080. - DOI - PMC - PubMed

Publication types

LinkOut - more resources